# Mexico Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Mexico HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Mexico (MEX) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $2.1B - Products: 48 - Buyer markets: 30 - Average CAGR: +27.7% - Global sector size: $782.3B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $306.3B | $1.2B | $113.7B | +8.4% | 21 | +0.3% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $154.6B | $1.4M | $61.4B | +158.6% | 14 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $26.0B | $295.4K | $33.4B | +55.3% | 5 | +0.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $18.7B | $72.0K | $32.6B | +11.5% | 2 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $4.0M | $23.0B | +5.6% | 3 | +0.0% | | HS 300220 - Vaccines: for human medicine | $27.6B | $181.1K | $22.9B | +5.3% | 6 | +0.0% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $411.6K | $16.8B | +7.4% | 3 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $28.0B | $27.5M | $16.1B | +23.6% | 6 | +0.1% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $6.9M | $15.9B | -5.9% | 8 | +0.0% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $19.9B | $238.3M | $13.6B | +44.2% | 6 | +0.6% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $6.6B | $285.9K | $9.7B | -12.0% | 4 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $15.9M | $8.5B | +10.6% | 3 | +0.2% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $6.1B | $465.9K | $8.3B | +41.7% | 2 | +0.1% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $6.1B | $14.7K | $7.2B | +26.5% | 3 | +0.0% | | HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $196.3 | $6.7B | -64.3% | 1 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $185.7M | $6.1B | +15.8% | 3 | +1.0% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $4.4B | $18.8M | $6.0B | +8.3% | 1 | +0.4% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $187.9M | $5.6B | +17.3% | 2 | +1.8% | | HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $6.8B | $44.6K | $5.0B | -2.2% | 2 | +0.0% | | HS 330300 - Perfumes and toilet waters | $6.6B | $82.4M | $4.0B | +18.5% | 2 | +0.8% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $48.3K | $3.3B | +4.8% | 2 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.1B | $1.2M | $2.9B | -5.5% | 2 | +0.0% | | HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $4.0M | $2.4B | +13.8% | 1 | +0.3% | | HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $1.6K | $2.4B | +36.6% | 1 | +0.0% | | HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $802.9 | $2.4B | +170.2% | 1 | +0.0% | | HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $39.2 | $2.2B | -28.4% | 1 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $2.4M | $2.1B | +14.5% | 1 | +0.1% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $226.8K | $2.0B | -0.9% | 1 | +0.0% | | HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $1.6M | $2.0B | +22.2% | 1 | +0.1% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $2.5M | $1.9B | +26.1% | 1 | +0.2% | | HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $12.4K | $1.8B | +11.1% | 1 | +0.0% | | HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $14.8K | $1.8B | -13.3% | 1 | +0.0% | | HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $12.9M | $1.7B | +33.9% | 1 | +0.6% | | HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $1.5M | $1.7B | +2.8% | 1 | +0.1% | | HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $74.7K | $1.7B | +22.3% | 1 | +0.1% | | HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $79.0 | $1.5B | -18.2% | 1 | +0.0% | | HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $41.6K | $1.5B | -23.4% | 1 | +3.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $29.9 | $1.4B | -7.3% | 1 | +0.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $3.0 | $1.4B | -29.5% | 1 | +0.0% | | HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $4.6M | $1.4B | +2.3% | 1 | +0.3% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $23.5M | $1.3B | +14.0% | 1 | +2.0% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $2.0B | $3.5 | $1.3B | -70.5% | 1 | +0.0% | | HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $502.1K | $1.3B | +1.1% | 1 | +0.0% | | HS 382370 - Industrial fatty alcohols | $1.0B | $413.2 | $1.3B | -0.8% | 1 | +0.0% | | HS 310530 - Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $33.5M | $1.3B | +1.5% | 1 | +0.6% | | HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $2.8K | $1.3B | +12.3% | 1 | +0.0% | | HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $1.2M | $1.3B | -4.7% | 1 | +0.1% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $131.9K | $1.2B | +2.0% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $154.6B calculated opportunity across 23 products. - Germany (DEU): $39.3B calculated opportunity across 12 products. - China (CHN): $38.4B calculated opportunity across 15 products. - Switzerland, Liechtenstein (CHE): $37.8B calculated opportunity across 5 products. - Slovenia (SVN): $31.5B calculated opportunity across 3 products. - Belgium (BEL): $30.6B calculated opportunity across 6 products. - Netherlands (NLD): $16.8B calculated opportunity across 4 products. - Italy (ITA): $13.4B calculated opportunity across 4 products. - Spain (ESP): $11.6B calculated opportunity across 6 products. - United Kingdom (GBR): $11.1B calculated opportunity across 5 products. - Canada (CAN): $10.9B calculated opportunity across 6 products. - Republic of Korea (KOR): $9.4B calculated opportunity across 5 products. ## Growth stars - HS 285390: +170.2% average CAGR, $2.4B calculated opportunity. - HS 300215: +158.6% average CAGR, $61.4B calculated opportunity. - HS 300214: +55.3% average CAGR, $33.4B calculated opportunity. - HS 382499: +44.2% average CAGR, $13.6B calculated opportunity. - HS 293379: +41.7% average CAGR, $8.3B calculated opportunity. - HS 282590: +36.6% average CAGR, $2.4B calculated opportunity. - HS 370790: +33.9% average CAGR, $1.7B calculated opportunity. - HS 382600: +26.5% average CAGR, $7.2B calculated opportunity. - HS 382319: +26.1% average CAGR, $1.9B calculated opportunity. - HS 300212: +23.6% average CAGR, $16.1B calculated opportunity. ## Diversification opportunities - HS 300490: 21 buyer markets, $113.7B calculated opportunity. - HS 300215: 14 buyer markets, $61.4B calculated opportunity. - HS 300439: 8 buyer markets, $15.9B calculated opportunity. - HS 300220: 6 buyer markets, $22.9B calculated opportunity. - HS 300212: 6 buyer markets, $16.1B calculated opportunity. - HS 382499: 6 buyer markets, $13.6B calculated opportunity. - HS 300214: 5 buyer markets, $33.4B calculated opportunity. - HS 284190: 4 buyer markets, $9.7B calculated opportunity. - HS 293359: 3 buyer markets, $23.0B calculated opportunity. - HS 293399: 3 buyer markets, $16.8B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.